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1.1 Introduction
Cancer accounts for approximately 30 percent of
the causes of death in Japan, and conquering
cancer is an important problem in the attempt to
maintain and increase Japanese people's health.
Recently, the mechanisms of the proliferation of
cancer cells, invasion and metastasis have been
clarified on the molecular level, and researches on
new therapies to make such specific molecules a
target (molecular target therapy) have progressed.
Therapy with molecular target drugs is expected
to lead to the reduction of side effects and the
treatment of refractory cancer and advanced
cancer, against which existing therapies are
revealing their limitations. The development of
molecular target drugs is being accelerated
throughout the world, and it must be promoted in
our country as well.
However, in Japan, it was pointed out that the
part combining the results of exploratory basic
researches and clinical practice was insufficient at
the “Intellectual conference on future ideal ways
of cancer research,” etc., and the necessity of
translational research (exploratory therapy or
exploratory clinical research) to bridge the gap
between basic researches and clinical practice has
been regarded as important.
In this report, we will state the trend of research
and development of molecular target drugs that
are highly expected as new therapies, and
consider measures to promote research and
development in this area.
1.2 System to promote
cancer researches
1.2.1  Measures taken in Japan
In our country, the promotion of cancer
researches has been attempted in multiple
ministry and agency, centering on the
“Comprehensive 10-year Strategy for Cancer
Control (1984-1993 (cumulative total of actual
research expenses was ¥102.4 billion))” and the
“Second Term Comprehensive 10-year Strategy for
Cancer Control (1994-2003 (cumulative total of
actual research expenses was (1994-2001) ¥147.1
billion))”. In the Millennium Project, cancer
researches were taken up as one of the themes,
and the target shown in Figure 1 was set as the
goal up to fiscal 2004.
Based on these policies, cancer researches in
Japan have been promoted and subsidized from
the Grant-in-Aid for Scientific Research by the
Ministry of Education, Culture, Sports, Science and
Technology (MEXT), and from the Grant-in-Aid for
Health Science Basic Research and Cancer
Research Subsidy by the Ministry of Health, Labour
and Welfare (MHLW).
In addition, future ideal ways of cancer research,
etc., that follow the “Second Term Comprehensive
Figure 1: Target for the Millennium Project in cancer
research
Source: "The Millennium Project" decided by the Prime Minister
on Dec. 19, 1999
• Discovery of more than 50 genes including disease-
related genes and drug reactivity-related genes.
• 50% reduction of anticancer drug-induced side effects,
such as vomiting and headache, by optimal medications
(tailor-made medicine), etc., for individual patients.
• Improvement of therapeutic results by optimal
medications for individual patients.
• Start of the development of epoch-making new drugs,
for example, a drug to improve the 5-year survival rate
by 20%.
10-year Strategy for Cancer Control” are now being
considered at the “Intellectual conference on
future ideal ways of cancer research,”
collaboratively held by MEXT and MHLW.
1.2.2  Measures taken in the United States
In the United States, since the National Cancer
Act was established under the Nixon
administration in 1971, the promotion of cancer
researches has been taken up on a national basis
centering on the National Cancer Institute (NCI).
NCI is the largest institute that belongs to the
National Institutes of Health (NIH). he budget of
NCI tends to increase year by year, and for fiscal
2002, approximately $4,180 million (approx. ¥501
billion) has been appropriated.
1.3 Characteristics and
therapies of cancer
1.3.1  Characteristics of cancer
Cancer is a disease attributable to genetic
abnormality caused by any tr igger such as
chemical substances called carcinogenic
substances, and radioactivity. Most cancer cells are
formed by repeating multiple genetic changes and
cell growth, as shown in Figure 2. A part of
cancers such as some forms of breast cancer and
colon cancer are gene related.
Cancer cells mainly have the following
characteristics, and recently many molecules
related to these characteristics have been clarified
(Table 1).
i) Abnormal cell growth due to abnormality in
the cell cycle, signal transmission system, cell
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Table 1: Major biological characteristics of cancer cells and the related molecules
Source: Authors’ own compilation
Characteristics Related molecules
Abnormal cell proliferation Proliferation-related molecule, signal transmission molecule, etc.
Invasion / Metastasis Adhesion molecule, protease, bone metastasis-related molecule, etc.
Vascularization Signal transmission molecule, protease, adhesion molecule
Drug resistance Membrane transport protein, etc.
Table 2: Major cancer therapies and their outlines
Source: Authors’ own compilation
Cancer therapy Outline
Chemotherapy Methods using anticancer drugs effective against cancer cells.  Multiple anticancer drugs are 
often used concomitantly.
Surgical therapy Methods to remove cancer cells by operation.  Recently, enhancement of a patient’s QOL is 
being attempted by low invasive endoscopic operation.
Radiotherapy Methods to destroy cancer cells by radiation.  Aiming to concentrate radiation on the area of 
focus as much as possible to reduce cytotoxicity in the surrounding normal cells; recently, 
methods using a gamma knife or ion beam have been developing rapidly.
Immunotherapy Methods to utilize the immune system, which detects molecules or pathogens recognized as 
non-self, to attack them.  A method using monoclonal antibody as a drug and a method using 
peptide vaccine are being developed.
Gene therapy Methods to enhance a patient’s immunity to cancer by introducing tumor suppressor genes to 
inhibit the development of cancer, or by introducing immune-related genes.
Figure 2: Conceptual flow chart of the multiple-stage
process of carcinogenesis
Source: “Cancer -- Challenge of health science” (1998), the
Second Term Comprehensive 10-year Strategy for
Cancer Control, Cancer Research Subsidy
differentiation, or cell death
(apoptosis).
ii) Formation of secondary tumors due to
abnormality of cell adhesion, and, thereby,
causing invasion or metastasis in the
surrounding organs.
iii) Vascularization that forms new blood vessels
to secure oxygen and nutrition.
iv) Drug resistance that makes drugs ineffective.
1.3.2  Cancer therapies
Major therapies for cancer are shown in Table 2.
In an actual therapy, multiple therapies are
combined occasionally.
1.3.3  Molecular target drugs
Anticancer drugs generally being used now
inhibit and stop abnormal cell proliferation, as one
of the characteristics of cancer cells, in order to
destroy cancer cells.
When cells proliferate, there are 4 steps in the
cell cycle including; i) gap phase of cell cycle and
cell differentiation phase (G1 phase), ii) DNA
synthesis phase (S phase), iii) cell division
preparatory phase (G2 phase), and iv) cell division
phase (M phase).
For cells frequently repeating the cell cycle, most
anticancer drugs have an action to inhibit their
DNA synthesis and cell division. For example, an
anticancer drug called “Taxol” has an action to
stop the progress of the M phase. However, cells
frequently repeating the cell cycle are not limited
to only cancer cells, but include normal cells such
as hematopoietic cells and hair root cells.
Therefore, most anticancer drugs also destroy
normal cells, causing side effects.
On the other hand, the molecular target therapy
is a therapy targeting molecules (Table 1)
characteristic to cancer cells, and reductions in
side effects may be expected from it. In addition,
it is expected that molecular target drugs have
possibilities to conquer intractable cancer such as
advanced cancer and refractory cancer (e.g. lung
cancer) for which there is the limit of the
traditional treatment.
Also, molecular target drugs are being used based
on individual patients' genetic abnormality and
excessive protein expression, an aspect of tailor-
made medicine (optimal therapy for individual
patients), and are highly expected to represent
what cancer therapy should be like after this.
In Table 3 and Figure 3, a comparison of the
characteristics between general anticancer drugs
and molecular target drugs are shown.
From the above, molecular target drugs are
highly expected as new types of anticancer drugs,
and various research and development are being
accelerated throughout the world.
For example, STI571 (brand name: Glivec),
developed as a drug for chronic myelogenous
leukemia (CML) by Novartis Pharma , Switzerland,
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Figure 3: Tumor regression of molecular target drugs
and general anticancer drugs, and the
relationship with occurrences of side effects
Source: Material prepared by Saburo Sone, M.D., Ph.D.,
professor at the University of Tokushima School of
Medicine
Table 3: Comparison between molecular target drugs and general anticancer drugs
Source: Authors’ compilation based on the material prepared by Saburo Sone, professor at the School of Medicine,
University of Tokushima
Subject item General anticancer drugs Molecular target drugs
Hypothesis of efficacy Empirical Based on theory.
Main action To destroy actively proliferating cells. To inhibit, prevent and add the effects of
molecules characteristic to cancer cells
Dosage setting Higher dosage is desirable, although side Optimal dose that may act on the target 
effects are taken into account. molecules.
Type of subject cancer All cancers such as solid cancer. Cancer with the target molecules.
Main efficacy Regression of cancer. To inhibit the progression of cancer.
was approved by the Food and Drug
Administration (FDA) only 3 years after the start of
clinical studies (May 2001). The drug is a
molecular target drug that only acts on genetic
products (protein with actions such as the
abnormal proliferation of leukemia cells and the
inhibition of apoptosis of blood cells) produced
by the abnormality of the BCR-ABL gene as a cause
of CML.
An anti-HER2 humanized monoclonal antibody,
trastuzumab (brand name: Herceptin), developed
as a breast cancer drug by Genentech, U.S.A., is a
molecular target drug for metastatic breast cancer
with excessive expression of a protein HER2. The
excessive expression of HER2 is observed in
approximately 20~25% of breast cancers.
Herceptin selectively binds to the HER2, and has a
cytotoxic effect on the cancer cells or an
inhibitory effect on proliferation.
1.3.4  Problem in the development of
molecular target drugs
As shown in Table 3, although efficacies of
general anticancer drugs are evaluated from the
regression of cancer, molecular target drugs are
mainly aimed to inhibit the progression of cancer,
and regression cannot be necessarily expected.
However, evaluations of anticancer drugs in
clinical studies are mainly based on the regression
of cancer. Therefore, the following criteria often
shown as therapeutic effects of molecular target
drugs have not been recognized as clinical
evaluations in treatment; stable disease (state
without exacerbation of cancer), time to
progression (time to malignancy of cancer once
again), and tumor dormancy (state of cancer
growth settling down). In the future, it will be
necessary to investigate the parameters for
effective clinical evaluations.
The development of a molecular target drug is
based on exploratory basic researches, and high
risk is associated with the stage to apply the drug
as a therapy in clinical studies. Therefore, in order
to promote the research and development of state-
of-the-art therapies such as molecular target drugs,
clinical trials conducted by the companies stated
later are not sufficient, and clinical studies in a
different form from the clinical trials are desired.
Therefore, the necessity of translational researches
is rapidly increasing.
1.4 System to promote
the development of
molecular target drugs
— Promotion of
translational researches —
1.4.1  What is Translational Research?
There is as yet no particular definition of
translational researches that has obtained world
consensus. In this report, we define this as
researches to apply the results of exploratory
basic researches for clinical studies to clinical
studies in the development of state-of-the-art
therapies such as molecular target drugs and
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Figure 4. Process of research and development of
molecular target drugs
Source: Authors’ own compilation
regenerative therapy, and we distinguish them
from clinical trials to obtain approval for drug, etc.
In Figure 4, the process of research and
development of molecular target drugs is shown.
Pharmaceutical development goes through basic
researches, non-clinical studies, and clinical
studies. Translational researches are likely to be in
the range of the non-clinical studies to the phase II
studies that can confirm the efficacy in humans.
In the current legal system, translational
researches are outside of the regulations of the
Pharmaceutical Affairs Law, as stated later.
However, translational researches are aimed at
establishing new therapies, and it is necessary to
sufficiently secure ethical and scientific validity in
clinical researches, and, therefore, it is also
necessary to conduct researches according to the
regulations of the Pharmaceutical Affairs Law and
arrange for a system to conduct studies in
translational researches.
1.4.2  Arrangement of legislation related to
translational researches
In pharmaceutical research and development, a
number of regulations have been made under
ordinances based on the Pharmaceutical Affairs
Law. Particularly, clinical studies (trials), which are
conducted by medical institutions entrusted by a
pharmaceutical company in order to obtain
approval for drugs, etc., are being conducted
according to Good Clinical Practice (GCP), strictly
securing ethical and scientific validity.
On the other hand, GCP is not applied to clinical
researches conducted mainly by researchers at
universities and medical institutions, and the
research data obtained there cannot be used for
the approval application of drugs.
Thus, in clinical studies conducted mainly by
universities and medical institutions, the research
results are not smoothly integrated with
pharmaceutical development and not required to
comply with the provisions of GCP. As a problem,
therefore, it was indicated that clinical studies
were in a status that they could be conducted
without sufficient consideration of the ethics and
safety for patients and scientific validity.
In the background of such present status, the
Ministry of Health, Labour and Welfare is
proceeding with the amendment of the
Pharmaceutical Affairs Law to extend its scope to
utilize the results related to clinical researches.
The proposed amendment was decided by
Cabinet meeting, and submitted to the 154 times
ordinary session of the Diet.
In the proposed amendment, the scope of
clinical tr ials is to be extended to clinical
researches conducted mainly by physicians and
medical institutions intending to apply for clinical
studies in the future (trial-type clinical researches).
This will make it possible to use the results
obtained from translational researches as part of
the application data, and to provide new medical
technologies to patients at an early stage while
securing the ethical and safety aspects.
Thus, the results of translational researches will
be easily combined to clinical trials, and the
development of molecular target drugs is
expected to accelerate.
1.4.3  Arrangement of the system to conduct
translational researches
At medical institutions such as university
hospitals, etc., efforts to arrange a system to
conduct translational researches are getting under
way.
As the first foothold of translational researches in
Japan, Kyoto University Hospital established its
Translational Research Center in April 2001. The
Translational Research Center has implemented a
public participation-type “Invited Research
Project” with the functions such as preparing
protocols, etc. and assessing the safety of the
adopted project; actually conducting the clinical
application, monitoring the safety and ethical
aspects, and analyzing the biostatics.
Kobe City Government, which is proceeding
with The Kobe Medical Industry Development
Project, plans to establish a Translational Research
Informatics Center in fiscal 2002, aiming to
arrange a database of clinical researches, etc., in
Japanese, in cooperation with the Ministry of
Education, Culture, Sports, Science and
Technology.
At the Council for Science and Technology Policy,
Cabinet Office, in the promotion strategy of
prioritized areas of life science (September 21,
2001) based on the Science and Technology Basic
Plan 2001-2005 (decided by Cabinet meeting on
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March 30, 2001), translational researches was
taken up as one of the fields for which measures
taken on a national basis should be strengthened,
and measures to promote this were started.
1.4.4  Measures taken for translational
researches in the United States
In the United States that has been extending the
scope of the state-of-the-art therapy, measures
taken for translational researches are being
accelerated.
The National Cancer Institute (NCI) supports
clinical researches being conducted by
approximately 10,000 researchers at
approximately 1,700 hospitals and cancer centers
in the United States.
NCI is already proceeding with several programs
for translational researches. For example, NCI
started Specialized Programs of Research
Excellence (SPOREs) to promote translational
researches in cancer researches in 1992, and
supports interdisciplinary research teams of
translational researches for specific human
cancers through public recruitment, etc. The
budget of SPOREs for fiscal 2002 is approximately
$107 million (approx. ¥12.8 billion), and is
expected to further increase in the future.
1.5 Conclusion
To conquer cancer is an important problem in
the attempt to maintain and increase Japanese
people's health. Particularly, it is desired that
therapies with less side effects, and therapies for
refractory cancer and advanced cancer be
established.
The research and development of molecular
target drugs taken up in this article are important
to our country as ways to explore new cancer
therapies. In the development of molecular target
drugs, translational researches are necessary to
promote clinical studies, simultaneously with the
promotion of basic researches.
To promote the development of molecular target
therapy, the following measures are necessary.
(1) Promotion of exploratory basic 
researches targeted for clinical
application
• Clarification of the mechanisms of the
proliferation of various cancers, and invasion
and metastasis, and identification of target
molecules by searching for tumor genes and
tumor suppressor genes.
• Search for drug reactivity-related genes, and
search for and invention of new substances.
(2) Arrangement of a system to support
researches
• Arrangement of an information management
system such as a database specialized for
cancer.
• Arrangement of a management system for
research materials such as genes and cells
(bio-resources).
(3) Arrangement of a system to conduct
translational researches
• Following the current ongoing amendment
to the Pharmaceutical Affairs Law, the
legislation arrangement for the scope of
clinical trials that is expected to extend in
the future.
• Arrangement of a system to verify scientific
validity, safety and ethics at institutions for
translational researches such as university
hospitals, and a system to deal with
unexpected emergencies, as exploratory
therapy is associated with high risk.
• Arrangement of participating teams
(researchers of basic molecular biology, basic
efficacy pharmacology, and clinical
medicine, etc.) to effectively promote
translational researches.
• To secure clinical research coordinators
(CRC) to conduct duties dealing with
subjects including informed consent, and
human resources to conduct data
management and analyses.
• To promote Japanese people's understanding
about clinical studies, so as to recruit
subjects more easily.
Through these measures, it is desired that new
therapies such as those utilizing molecular target
drugs be established to attain early realization of
therapies with less side effects and improvement
of the curing rate of cancer.
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